Min Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Min Cui has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Xiao Yu
Key Laboratory Experimental Teratology of the Ministry of Education and Department of Physiology, School of Basic Medical Sciences, Shandong University, Jinan, China
4 shared publications - Jin-Peng Sun
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China; Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China
3 shared publications You-Chen Song
Department of Medical Biophysics University of Toronto Toronto ON Canada
2 shared publications- Yunfei Xu
Department of General Surgery, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, 250012, Shandong, China
2 shared publications Zhi-Gang Xu
Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology School of Life Sciences Shandong University Jinan China
2 shared publicationsZhong-Liang Zhu
School of Life Sciences University of Science and Technology of China Hefei China
2 shared publications
Latest Publications
- 25 March 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (5) , e52141
PTP-MEG2 regulates quantal size and fusion pore opening through two distinct structural bases and substrates
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 25 March 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (5) , e52141
PTP-MEG2 regulates quantal size and fusion pore opening through two distinct structural bases and substrates
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- Open Access
PTP-MEG2 regulates quantal size and fusion pore opening through two distinct structural bases and substrates
Tyrosine phosphorylation of secretion machinery proteins is a crucial regulatory mechanism for exocytosis. However, the participation of protein tyrosine phosphatases (PTPs) in different exocytosis stages has not been defined. Here we demonstrated that PTP-MEG2 controls multiple steps of catecholamine secretion. Biochemical and crystallographic analyses revealed key residues that the interactions between govern the PTP-MEG2 and NSF-pY 83 site, specify PTP-MEG2 substrate selectivity and modulate the fusion of catecholamine-containing vesicles. Unexpectedly, delineation of PTP-MEG2 mutants along with the NSF binding interface revealed that PTP-MEG2 controls the fusion pore opening through non-NSF dependent mechanisms. Utilizing bioinformatics search and biochemical and electrochemical screening approaches, we discovered that PTP-MEG2 regulates the opening and extension of the fusion pore by dephosphorylating the DYNAMIN2-pY 125 and MUNC18-1-pY 145 site. Further structural and biochemical analysis confirmed the interaction of PTP-MEG2 with MUNC18-1-pY 145 or DYNAMIN2-pY 125 through a distinct structural basis compared with that of the NSF-pY 83 site. Our studies extended mechanistic insights in complex exocytosis processes. HIGHLIGHTS: PTP-MEG2 regulates multiple steps of exocytosis. A crystal structure of the PTP-MEG2/phosphor-NSF-pY 83 segment was obtained. Functional delineation of the PTP-MEG2/NSF interface led to the discovery of new PTP-MEG2 substrates. PTP-MEG2 regulates fusion pore opening and extension through the DYNAMIN2-pY 125 site and MUNC18-1 pY 145 site. The distinct structural basis of the recognition of substrates by PTP-MEG2 allows selective inhibitor design.
Open AccessPTP-MEG2 regulates quantal size and fusion pore opening through two distinct structural bases and substrates
Tyrosine phosphorylation of secretion machinery proteins is a crucial regulatory mechanism for exocytosis. However, the participation of protein tyrosine phosphatases (PTPs) in different exocytosis stages has not been defined. Here we demonstrated that PTP-MEG2 controls multiple steps of catecholamine secretion. Biochemical and crystallographic analyses revealed key residues that the interactions between govern the PTP-MEG2 and NSF-pY 83 site, specify PTP-MEG2 substrate selectivity and modulate the fusion of catecholamine-containing vesicles. Unexpectedly, delineation of PTP-MEG2 mutants along with the NSF binding interface revealed that PTP-MEG2 controls the fusion pore opening through non-NSF dependent mechanisms. Utilizing bioinformatics search and biochemical and electrochemical screening approaches, we discovered that PTP-MEG2 regulates the opening and extension of the fusion pore by dephosphorylating the DYNAMIN2-pY 125 and MUNC18-1-pY 145 site. Further structural and biochemical analysis confirmed the interaction of PTP-MEG2 with MUNC18-1-pY 145 or DYNAMIN2-pY 125 through a distinct structural basis compared with that of the NSF-pY 83 site. Our studies extended mechanistic insights in complex exocytosis processes. HIGHLIGHTS: PTP-MEG2 regulates multiple steps of exocytosis. A crystal structure of the PTP-MEG2/phosphor-NSF-pY 83 segment was obtained. Functional delineation of the PTP-MEG2/NSF interface led to the discovery of new PTP-MEG2 substrates. PTP-MEG2 regulates fusion pore opening and extension through the DYNAMIN2-pY 125 site and MUNC18-1 pY 145 site. The distinct structural basis of the recognition of substrates by PTP-MEG2 allows selective inhibitor design.
- Open Access
- 12 June 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (7) , 2631-2646
A cullin 4B-RING E3 ligase complex fine-tunes pancreatic δ cell paracrine interactions
Somatostatin secreted by pancreatic δ cells mediates important paracrine interactions in Langerhans islets, including maintenance of glucose metabolism through the control of reciprocal insulin and glucagon secretion. Disruption of this circuit contributes to the development of diabetes. However, the precise mechanisms that control somatostatin secretion from islets remain elusive. Here, we found that a super-complex comprising the cullin 4B-RING E3 ligase (CRL4B) and polycomb repressive complex 2 (PRC2) epigenetically regulates somatostatin secretion in islets. Constitutive ablation of CUL4B, the core component of the CRL4B-PRC2 complex, in δ cells impaired glucose tolerance and decreased insulin secretion through enhanced somatostatin release. Moreover, mechanistic studies showed that the CRL4B-PRC2 complex, under the control of the δ cell–specific transcription factor hematopoietically expressed homeobox (HHEX), determines the levels of intracellular calcium and cAMP through histone posttranslational modifications, thereby altering expression of the Cav1.2 calcium channel and adenylyl cyclase 6 (AC6) and modulating somatostatin secretion. In response to high glucose levels or urocortin 3 (UCN3) stimulation, increased expression of cullin 4B (CUL4B) and the PRC2 subunit histone-lysine N-methyltransferase EZH2 and reciprocal decreases in Cav1.2 and AC6 expression were found to regulate somatostatin secretion. Our results reveal an epigenetic regulatory mechanism of δ cell paracrine interactions in which CRL4B-PRC2 complexes, Cav1.2, and AC6 expression fine-tune somatostatin secretion and facilitate glucose homeostasis in pancreatic islets.
- 12 June 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (7) , 2631-2646
Open AccessA cullin 4B-RING E3 ligase complex fine-tunes pancreatic δ cell paracrine interactions
Somatostatin secreted by pancreatic δ cells mediates important paracrine interactions in Langerhans islets, including maintenance of glucose metabolism through the control of reciprocal insulin and glucagon secretion. Disruption of this circuit contributes to the development of diabetes. However, the precise mechanisms that control somatostatin secretion from islets remain elusive. Here, we found that a super-complex comprising the cullin 4B-RING E3 ligase (CRL4B) and polycomb repressive complex 2 (PRC2) epigenetically regulates somatostatin secretion in islets. Constitutive ablation of CUL4B, the core component of the CRL4B-PRC2 complex, in δ cells impaired glucose tolerance and decreased insulin secretion through enhanced somatostatin release. Moreover, mechanistic studies showed that the CRL4B-PRC2 complex, under the control of the δ cell–specific transcription factor hematopoietically expressed homeobox (HHEX), determines the levels of intracellular calcium and cAMP through histone posttranslational modifications, thereby altering expression of the Cav1.2 calcium channel and adenylyl cyclase 6 (AC6) and modulating somatostatin secretion. In response to high glucose levels or urocortin 3 (UCN3) stimulation, increased expression of cullin 4B (CUL4B) and the PRC2 subunit histone-lysine N-methyltransferase EZH2 and reciprocal decreases in Cav1.2 and AC6 expression were found to regulate somatostatin secretion. Our results reveal an epigenetic regulatory mechanism of δ cell paracrine interactions in which CRL4B-PRC2 complexes, Cav1.2, and AC6 expression fine-tune somatostatin secretion and facilitate glucose homeostasis in pancreatic islets.
- Open Access
- 23 October 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (21) , 5050-5067
Different downstream signalling of CCK1receptors regulates distinct functions of CCK in pancreatic beta cells
Background and Purpose: Cholecystokinin (CCK) is secreted by intestinal I cells and regulates important metabolic functions. In pancreatic islets, CCK controls beta cell functions primarily through CCK1receptors, but the signalling pathways downstream of these receptors in pancreatic beta cells are not well defined.Experimental Approach: Apoptosis in pancreatic beta cell apoptosis was evaluated using Hoechst‐33342 staining, TUNEL assays and Annexin‐V‐FITC/PI staining. Insulin secretion and second messenger production were monitored using ELISAs. Protein and phospho‐protein levels were determined by Western blotting. A glucose tolerance test was carried out to examine the functions of CCK‐8s in streptozotocin‐induced diabetic mice.Key Results: The sulfated carboxy‐terminal octapeptide CCK26‐33amide (CCK‐8s) activated CCK1receptors and induced accumulation of both IP3and cAMP. Whereas Gq‐PLC‐IP3signalling was required for the CCK‐8s‐induced insulin secretion under low‐glucose conditions, Gs‐PKA/Epac signalling contributed more strongly to the CCK‐8s‐mediated insulin secretion in high‐glucose conditions. CCK‐8s also promoted formation of the CCK1receptor/β‐arrestin‐1 complex in pancreatic beta cells. Using β‐arrestin‐1 knockout mice, we demonstrated that β‐arrestin‐1 is a key mediator of both CCK‐8s‐mediated insulin secretion and of its the protective effect against apoptosis in pancreatic beta cells. The anti‐apoptotic effects of β‐arrestin‐1 occurred through cytoplasmic late‐phase ERK activation, which activates the 90‐kDa ribosomal S6 kinase‐phospho–Bcl‐2‐family protein pathway.Conclusions and Implications: Knowledge of different CCK1receptor‐activated downstream signalling pathways in the regulation of distinct functions of pancreatic beta cells could be used to identify biased CCK1receptor ligands for the development of new anti‐diabetic drugs.
- 23 October 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (21) , 5050-5067
Open AccessDifferent downstream signalling of CCK1receptors regulates distinct functions of CCK in pancreatic beta cells
Background and Purpose: Cholecystokinin (CCK) is secreted by intestinal I cells and regulates important metabolic functions. In pancreatic islets, CCK controls beta cell functions primarily through CCK1receptors, but the signalling pathways downstream of these receptors in pancreatic beta cells are not well defined.Experimental Approach: Apoptosis in pancreatic beta cell apoptosis was evaluated using Hoechst‐33342 staining, TUNEL assays and Annexin‐V‐FITC/PI staining. Insulin secretion and second messenger production were monitored using ELISAs. Protein and phospho‐protein levels were determined by Western blotting. A glucose tolerance test was carried out to examine the functions of CCK‐8s in streptozotocin‐induced diabetic mice.Key Results: The sulfated carboxy‐terminal octapeptide CCK26‐33amide (CCK‐8s) activated CCK1receptors and induced accumulation of both IP3and cAMP. Whereas Gq‐PLC‐IP3signalling was required for the CCK‐8s‐induced insulin secretion under low‐glucose conditions, Gs‐PKA/Epac signalling contributed more strongly to the CCK‐8s‐mediated insulin secretion in high‐glucose conditions. CCK‐8s also promoted formation of the CCK1receptor/β‐arrestin‐1 complex in pancreatic beta cells. Using β‐arrestin‐1 knockout mice, we demonstrated that β‐arrestin‐1 is a key mediator of both CCK‐8s‐mediated insulin secretion and of its the protective effect against apoptosis in pancreatic beta cells. The anti‐apoptotic effects of β‐arrestin‐1 occurred through cytoplasmic late‐phase ERK activation, which activates the 90‐kDa ribosomal S6 kinase‐phospho–Bcl‐2‐family protein pathway.Conclusions and Implications: Knowledge of different CCK1receptor‐activated downstream signalling pathways in the regulation of distinct functions of pancreatic beta cells could be used to identify biased CCK1receptor ligands for the development of new anti‐diabetic drugs.
- 1 August 2010
- Published by Elsevier in Neurobiology of Disease
- Vol. 39 (2) , 138-147
Blocking TRAIL-DR5 signaling with soluble DR5 reduces delayed neuronal damage after transient global cerebral ischemia
- 1 August 2010
- Published by Elsevier in Neurobiology of Disease
- Vol. 39 (2) , 138-147
Blocking TRAIL-DR5 signaling with soluble DR5 reduces delayed neuronal damage after transient global cerebral ischemia
- 31 January 2007
- Published by Elsevier in Molecular Immunology
- Vol. 44 (1-3) , 209
Discovery of key complement components and relevant miRNA in HBV transgenic mouse model of HCC development
- 31 January 2007
- Published by Elsevier in Molecular Immunology
- Vol. 44 (1-3) , 209
Discovery of key complement components and relevant miRNA in HBV transgenic mouse model of HCC development